Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company’s first patent fi ...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the "Company") today announced that it has entered into a joint development agreement with Manoira Corporation ("Manoira"), a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics for veterinary and livestock applications. Under the terms of the joint development agreement, Manoira will evaluate Con ...

Core Insights - Conduit Pharmaceuticals has secured a composition of matter patent for its lead asset, AZD1656, from the Korean Intellectual Property Office, enhancing its global intellectual property position and facilitating clinical development and strategic partnerships [1][2] - The patent approval follows similar grants in the U.S., Japan, and Australia, indicating a robust international patent strategy that supports Conduit's growth in the Asia-Pacific pharmaceutical market [1][2] - The company aims to leverage its innovative approach to compound development, utilizing artificial intelligence and cybernetics, to create long-term value through global partnerships and licensing deals [2] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company focused on developing Phase 2-ready assets through an integrated platform-driven approach [2] - The leadership team, including Dr. Andrew Regan and Dr. Freda Lewis-Hall, emphasizes a departure from traditional pharmaceutical business models by seeking exits through third-party licensing after successful clinical trials [2]